Organon & Co. (NYSE:OGN) Announces Quarterly Dividend of $0.02

Organon & Co. (NYSE:OGN) declared a quarterly dividend on Friday, July 31st. Shareholders of record on Friday, August 14th will be given a dividend of 0.02 per share on Thursday, September 10th. This represents a c) dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th.

Organon & Co. has a dividend payout ratio of 2.0% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Organon & Co. to earn $3.44 per share next year, which means the company should continue to be able to cover its $0.08 annual dividend with an expected future payout ratio of 2.3%.

Organon & Co. Stock Performance

Shares of OGN traded up $0.01 during trading hours on Friday, reaching $13.55. 2,689,351 shares of the company traded hands, compared to its average volume of 6,106,729. The company has a quick ratio of 1.42, a current ratio of 1.97 and a debt-to-equity ratio of 9.47. The business has a fifty day moving average price of $13.47 and a 200-day moving average price of $10.38. Organon & Co. has a 12-month low of $5.69 and a 12-month high of $13.60. The stock has a market capitalization of $3.56 billion, a P/E ratio of 14.58, a P/E/G ratio of 1.25 and a beta of 1.54.

Organon & Co. (NYSE:OGN) last issued its earnings results on Friday, July 31st. The company reported $0.85 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.87 by ($0.02). The firm had revenue of $1.56 billion during the quarter, compared to analysts’ expectations of $1.57 billion. Organon & Co. had a return on equity of 99.95% and a net margin of 3.99%. Equities analysts anticipate that Organon & Co. will post 3.23 EPS for the current fiscal year.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.